Considering its established role in CD4+ T cells and what is currently known in CD8+, inhibiting DOT1L may provide a therapeutic target for dampening adverse CD8+ T cell responses including those in autoimmunity whilst augmenting DOT1L function may facilitate heightened CD8+ T cell responses important in combating viral infections and cancers. The gene discussed is CD8A; the disease is cancer.